Organogenesis (NASDAQ:ORGO) Announces Quarterly Earnings Results

Organogenesis (NASDAQ:ORGO - Get Free Report) announced its quarterly earnings results on Thursday. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.07, Zacks reports. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The business had revenue of $126.66 million during the quarter, compared to the consensus estimate of $109.60 million. Organogenesis updated its FY 2025 guidance to EPS.

Organogenesis Stock Performance

Shares of NASDAQ ORGO traded down $0.80 during mid-day trading on Monday, reaching $5.41. 5,949,141 shares of the company were exchanged, compared to its average volume of 1,055,856. The stock has a market capitalization of $680.18 million, a P/E ratio of -90.17 and a beta of 1.77. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. The company's 50-day simple moving average is $3.42 and its 200-day simple moving average is $3.25. Organogenesis has a twelve month low of $2.17 and a twelve month high of $6.69.

Insider Activity at Organogenesis

In other news, CEO Gary S. Gillheeney sold 18,416 shares of the business's stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $3.65, for a total transaction of $67,218.40. Following the completion of the sale, the chief executive officer now owns 3,400,778 shares in the company, valued at $12,412,839.70. The trade was a 0.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 278,116 shares of company stock worth $991,190. Insiders own 36.90% of the company's stock.

Remove Ads

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.